CAMBRIDGE, Mass.--(ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the initial data from its Phase 1/2 trial of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), will be presented at the ESMO 2012 Congress of the European Society for Medical Oncology (ESMO) being held in Vienna, Austria, September 28 to October 2, 2012.)--
Results from the dose-escalation portion of the ongoing Phase 1/2 trial will be featured in an oral presentation on Saturday, September 29, 2012 and will also be highlighted in a company-sponsored investor conference call to be webcast live from Vienna.
The schedule and meeting location for the session, together with the abstract information and details on the investor briefing, are listed below:
Oral Presentation at ESMO
Title: A First-in-Human Dose-Finding Study of the ALK/EGFR Inhibitor AP26113 in Patients with Advanced Malignancies
Oral Session: Developmental Therapeutics Session
Date & Time: Saturday, September 29, 11:15 a.m. (CEST)
Presenter: Scott Gettinger, M.D. (Yale University School of Medicine)
Location: Hall E
ARIAD will hold an investor conference call and webcast on Monday, October 1, 2012, at 8:00 a.m. ET to discuss the data from the ongoing Phase 1/2 trial of AP26113. Scott Gettinger, M.D., Associate Professor of Medicine at Yale University School of Medicine, will join members of ARIAD’s management team for the briefing from Vienna. This call will be webcast live and can be accessed by visiting the investor relations section of ARIAD’s website at: http://investor.ariad.com or by dialing 1-866-700-0161 (domestic) or 617-213-8832 (international) five minutes prior to the start time and providing the pass code 50829176.
A replay of this investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived for three weeks.
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).